Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Share-based Compensation: 2019-2025

Historic Share-based Compensation for Avidity Biosciences (RNA) over the last 7 years, with Sep 2025 value amounting to $19.0 million.

  • Avidity Biosciences' Share-based Compensation rose 35.00% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.6 million, marking a year-over-year increase of 45.73%. This contributed to the annual value of $51.4 million for FY2024, which is 34.38% up from last year.
  • Latest data reveals that Avidity Biosciences reported Share-based Compensation of $19.0 million as of Q3 2025, which was up 7.73% from $17.7 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Share-based Compensation peaked at $19.0 million during Q3 2025, and registered a low of $3.7 million during Q1 2021.
  • Over the past 3 years, Avidity Biosciences' median Share-based Compensation value was $12.8 million (recorded in 2024), while the average stood at $13.1 million.
  • Data for Avidity Biosciences' Share-based Compensation shows a peak YoY surged of 724.28% (in 2021) over the last 5 years.
  • Avidity Biosciences' Share-based Compensation (Quarterly) stood at $4.5 million in 2021, then skyrocketed by 61.80% to $7.3 million in 2022, then spiked by 34.73% to $9.8 million in 2023, then spiked by 43.76% to $14.2 million in 2024, then soared by 35.00% to $19.0 million in 2025.
  • Its last three reported values are $19.0 million in Q3 2025, $17.7 million for Q2 2025, and $17.7 million during Q1 2025.